Description
It is well established that optimising glycaemic management decreases the risk of microvascular and macrovascular complications. A reduction of 1% glycated haemoglobin (HbA1c) has been associated with reductions in microvascular complications by 37%, myocardial infarction by 14% and death related to diabetes by 21%. Delayed treatment intensification to injectable therapy may be due to a myriad of reasons that may include concerns regarding problematic hypoglycaemia, complex or burdensome regimens, interference with daily living, social stigma and weight gain. Fear of hypoglycaemia was identified as a key barrier to treatment intensification. 75.5% of healthcare professionals reported they would treat more aggressively if it weren’t for the risk of hypoglycaemia with insulin.